REZOLUTE, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
REZOLUTE, INC. (RZLT) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $2.23 million for the 12-month period ending 2019-06-30, per its 10-K filed 2020-10-13.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2020-10-13
- REZOLUTE, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2019-06-30 was $0.00.
- REZOLUTE, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2019-03-31 was $2.23M.
- REZOLUTE, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2019 was $2.23M.
- REZOLUTE, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2014 was $2.92M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2019-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-13 | $2.23M derived: sum of 2 quarters · filed 2020-10-13 | $2.23M 10-K · filed 2020-10-13 | |
| 2019-03-31 | $2.23M 10-Q · filed 2020-05-14 | $2.23M 10-Q · filed 2020-05-14 | ||
| 2014-06-30 | $2.92M 10-K · filed 2015-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |